# US 2023/0058044 A1 · Chimeric antigen receptor to carbohydrate antigens

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2023/0058044 A1
- Document ID: US20230058044A1
- Status: Published application
- Kind: A1
- Application number: 17/779,704
- Filed: 2020-11-25
- Published: 2023-02-23
- Earliest claimed: 2019-11-26
- Applicants: Ramot At Tel-Aviv University Ltd.; Ichilov Tech Ltd.; Yeda Research and Development Co. Ltd.
- Inventors: Vered PADLER-KARAVANI; Yafit ATIYA-NASAGI; Ron AMON; Anat GLOBERSON LEVIN; Tova WAKS; Moran RAWET-SLOBODKIN; Lihi NINIO MANY; Zelig ESHHAR
- Web page: https://patentgrep.com/patent/US20230058044A1

## CPC

- A61P 35/00: Antineoplastic agents
- C07K 14/7051: {T-cell receptor (TcR)-CD3 complex}
- A61K 40/11: T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
- A61K 40/31: Chimeric antigen receptors [CAR]
- A61K 40/4202: {Receptors, cell surface antigens or cell surface determinants}
- A61K 40/4256: {Tumor associated carbohydrates}
- C07K 14/70521: {CD28, CD152}
- C07K 14/70535: {Fc-receptors, e.g. CD16, CD32, CD64 (CD2314/705F)}
- C07K 16/30: from tumour cells
- C12N 5/0636: {T lymphocytes}
- A61K 2239/31: characterized by the route of administration
- A61K 2239/38: characterised by the dose, timing or administration schedule
- A61K 2239/50: Colon
- A61K 2239/54: Pancreas
- A61K 2239/59: Reproductive system, e.g. uterus, ovaries, cervix or testes
- C07K 2317/33: Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
- C07K 2317/622: Single chain antibody (scFv)
- C07K 2317/73: Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K 2317/92: Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
- C07K 2319/02: containing a signal sequence
- C07K 2319/03: containing a transmembrane segment
- C07K 2319/22: containing a Strep-tag
- C07K 2319/33: fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
- C12N 2510/00: Genetically modified cells
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

The present invention discloses chimeric antigen receptors that specifically recognize and bind to SLe A carbohydrate antigen with high specificity and selectivity. The invention further provides lymphocytic cells, such as T cells, comprising said CARs, compositions comprising said cells or CARs as well as uses thereof.

## Claims

### Claim at position 1

1-53. (canceled)

### Claim 54

A chimeric antigen receptor (CAR) comprising an antigen binding domain that binds specifically to Sialyl Lewis A glycan (SLeA), wherein the antigen binding domain comprises three complementarity determining regions (CDRs) and four framework (FR) domains of a heavy-chain variable domain (VH) having amino acid sequence as set forth in SEQ ID NO: 1 and three CDRs and four FRs of a light-chain variable domain (VL) having amino acid sequence as set forth in SEQ ID NO: 4, or an analog thereof having at least 90% sequence identity to said sequences.

### Claim 55 (depends on 53)

The CAR according to claim 53, wherein the VH-CDR1 comprises amino acid sequence selected from SEQ ID NOs: 6 and 30, the VH-CDR2 comprises amino acid sequence selected from 7 and 31, the VH-CDR3 comprises amino acid sequence SEQ ID NO: 8, and CDRs 1, 2, and 3 of the VL domain comprise amino acid sequences SEQ ID NOs: 9, 10, and 11, respectively.

### Claim 56 (depends on 55)

The CAR according to claim 55, wherein the CAR is characterized by at least one of:
(i) the VH-CDR2 comprises at least one non-conservative substitution;
(ii) the VH-CDR2 comprises amino acid sequence selected from SEQ ID NO: 12 and 36;
(iii) the VH domain comprises amino acid sequence set forth in SEQ ID NO: 2 and the VL domain comprises amino acid sequence SEQ ID NO: 4;
(iv) wherein the antigen binding domain further comprises at least 2 or 3, or 4 non-conservative substitutions of amino acids in the framework sequence of a domain selected from (a) the VH domain; (b) the VL domain; and (c) both VH and VL domains.

### Claim 57 (depends on 56)

The CAR according to claim 56, characterized by at least one of: (i) at least 2 of said non-conservative substitutions is for proline amino acid residue; and (ii) the non-conservative substitutions are at a position selected from positions 1, 110, 114 of SEQ ID NO: 1 or 2, position 22 of SEQ ID NO: 4 and any combination thereof.

### Claim 58 (depends on 57)

The CAR according to claim 57, wherein the (i) antigen binding domain comprises a substitution of the amino acid at position 1 of SEQ ID NO: 1 or of SEQ ID NO: 2 for a positively charged amino acid residue or (ii) antigen binding domain comprises a substitution of the amino acid at position 1 of SEQ ID NO: 1 or of SEQ ID NO: 2 for a positively charged amino acid residue selected from Lys and Arg.

### Claim 59 (depends on 53)

The CAR according to claim 53, wherein:
(i) the VH-CDR 1, 2 and 3 comprise amino acid sequences SEQ ID NOs: 30, 12, and 8, respectively, the VL-CDRs 1, 2 and 3 comprise amino acid sequences SEQ ID NOs: 9, 10 and 11, respectively, VH-FRs 1, 2 and 4 comprise amino acid sequences SEQ ID NOs: 39, 42 and 43, respectively, and the VL-FR 1 comprises acid sequences SEQ ID NO: 44;
(ii) the CDRs 1, 2, and 3 of the VH domain comprises amino acid sequences SEQ ID NOs: 30, 36 and 8, respectively, the CDRs 1, 2, and 3 of the VL domain comprise amino acid sequences SEQ ID NOs: 9, 10 and 11, the VH-FRs 1, 2 and 4 comprise amino acid sequences SEQ ID NOs: 40, 42 and 43, respectively, and the VL-FR1 comprises amino acid sequences SEQ ID NO: 44;
(iii) the CDRs 1, 2, and 3 of the VH domain comprise amino acid sequences SEQ ID NOs: 30, 36 and 8, respectively, the CDRs 1, 2, and 3 of the VL domain comprise amino acid sequences SEQ ID NOs: 9, 10 and 11, respectively, the VH-FRs 1, 2, 3 and 4 comprise amino acid sequences SEQ ID NOs: 40, 42, 45 and 43, respectively, and the VL-FR1, 2, 3 and 4 comprise amino acid sequences SEQ ID NOs: 44, 46, 47 and 48, respectively; or
(iv) the VH domain comprises amino acid sequence SEQ ID NO: 3 and the VL domain comprises amino acid sequence SEQ ID NO: 5.

### Claim 60 (depends on 53)

The CAR according to claim 53, characterized by at least one of:
(i) the CAR further comprising at least one conservative substitution in the framework(s) of the VH domain and/or VL domain, wherein the resulted VH domain has at least 90% sequence identity to SEQ ID NO: 3 and/or the resulted VL domain has at least 90% sequence identity to SEQ ID NO: 5;
(ii) the VH and the VL domains are linked by a spacer to form a single chain variable fragment (scFv); and
(iii) wherein the VH and the VL domains are linked by a spacer to form a scFv, wherein the spacer comprises amino acid sequence comprising from 2 to 6 repetitions of the amino acid sequence set forth in SEQ ID NO: 16.

### Claim 61 (depends on 60)

The CAR according to claim 60, wherein the scFv comprises amino acid sequence selected from SEQ ID NO: 15 and 37 or an analog thereof having at least 90% sequence identity to said sequences.

### Claim 62 (depends on 53)

The CAR according to claim 53, wherein the CAR comprises a transmembrane domain (TM domain), a costimulatory domain and an activation domain.

### Claim 63 (depends on 62)

The CAR according to claim 62, wherein the CAR is characterized by at least one of:
(i) the TM domain is a TM domain of a receptor selected from CD28 and CD8, or an analog thereof having at least 85% amino acid identity to said sequences;
(ii) the costimulatory domain is selected from a costimulatory domain of a protein selected from CD28, 4-1BB, OX40, iCOS, CD27, CD80, and CD70, an analog thereof having at least 85% amino acid identity to the original sequence and any combination thereof;
(iii) the TM domain and the costimulatory domain are both derived from CD28;
(iv) wherein the antigen binding domain is linked to the TM domain via a spacer;
(v) wherein the activation domain is selected from FcRγ and CD3-ζ activation domains; and
(vi) further comprising a leading peptide.

### Claim 64 (depends on 63)

The CAR according to claim 63, wherein the CAR is characterized by at least one of:
(i) the TM domain and the costimulatory domain have amino acid sequence SEQ ID NO: 17 or an analog thereof having at least 85% amino acid identity to the sequence;
(ii) the spacer comprises amino acid sequence comprising from 1 to 4 repetitions of amino acid sequence SEQ ID NO: 16;
(iii) the activation domain is FcRγ having amino acid sequence SEQ ID NO: 18 or an analog thereof having at least 85% amino acid identity to the original sequence; and
(vi) the leading peptide has amino acid sequence SEQ ID NO: 19 or an analog thereof having at least 85% amino acid identity.

### Claim 65 (depends on 53)

The CAR according to claim 53, comprising amino acid sequence selected from SEQ ID NO: 20 and 38.

### Claim 66 (depends on 53)

A nucleic acid molecule, encoding the CAR according to claim 53 or the construct or vector comprising the nucleic acid molecule.

### Claim 67 (depends on 66)

The nucleic acid molecule according to claim 66, wherein the nucleic acid molecule is characterized by at least one of:
(i) the nucleic acid molecule encodes amino acid sequence selected from SEQ ID NO: 3, SEQ ID NO: 5 and both SEQ ID NOs: 3 and 5;
(ii) the nucleic acid molecule comprises a nucleic acid sequence selected from SEQ ID NO: 13, SEQ ID NO: 14, a variant of SEQ ID NO: 13 or 14 having at least 95% sequence identity to the sequence(s), and a combination thereof
(iii) the nucleic acid molecule encodes amino acid sequence SEQ ID NO: 15;
(iv) the nucleic acid molecule comprises nucleic acid sequence SEQ ID NO: 21 or a variant thereof having at least 95% sequence identity to said sequence;
(v) the nucleic acid molecule encodes amino acid sequence selected from the group consisting of SEQ ID NOs: 17, 18, 19, an analog thereof, and any combination thereof;
(vi) the nucleic acid molecule comprises a nucleic acid sequence selected from the group consisting of SEQ ID NO: 22, 23, 24, a variant thereof having at least 95% sequence identity to said sequence(s), and a combination thereof;
(vi) the nucleic acid molecule encodes amino acid sequence selected from the group consisting of SEQ ID NO: 20, SEQ ID NO: 28, and SEQ ID NO: 38;
(vii) the nucleic acid molecule comprises a nucleic acid sequence selected from the group consisting of SEQ ID NO: 25, SEQ ID NO: 29, and a variant thereof having at least 95% sequence identity to the original sequence.

### Claim 68 (depends on 54)

A cell comprising the CAR according to claim 54 or the nucleic acid molecule encoding same or the construct or vector comprising the nucleic acid molecule.

### Claim 69 (depends on 56)

The cell according to claim 56, wherein the cell is characterized by at least one of:
(i) the cell expresses or capable of expressing the CAR; and
(ii) the cell is selected from a T cell and a natural killer (NK) cell.

### Claim 70 (depends on 54)

T cells comprising the CAR according to claim 54 or the nucleic acid encoding the CAR.

### Claim 71 (depends on 68)

A pharmaceutical composition comprising a plurality of cells according claim 68, and a pharmaceutically acceptable carrier.

### Claim 72 (depends on 68)

A method for treating cancer in a subject in need thereof comprising administering a therapeutically effective amount of cells according to claim 68 or a pharmaceutical composition comprising same.

### Claim 73 (depends on 72)

A method according to claim 72, wherein the cancer is selected from lung adenocarcinoma, pancreatic adenocarcinoma, colon adenocarcinoma, Her-2 negative breast carcinoma and pharynx squamous cell carcinoma.
